Prelude Therapeutics Incorporated (PRLD) NASDAQ
4.66
+0.02(+0.43%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.66
+0.02(+0.43%)
Currency In USD
| Previous Close | 4.64 |
| Open | 4.57 |
| Day High | 4.81 |
| Day Low | 4.42 |
| 52-Week High | 5.54 |
| 52-Week Low | 0.75 |
| Volume | 392,123 |
| Average Volume | 393,537 |
| Market Cap | 259.69M |
| PE | -4.66 |
| EPS | -1 |
| Moving Average 50 Days | 3.99 |
| Moving Average 200 Days | 2.25 |
| Change | 0.02 |
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
GlobeNewswire Inc.
Feb 03, 2026 2:00 PM GMT
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, tod
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
GlobeNewswire Inc.
Dec 06, 2025 4:00 PM GMT
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First di
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 12, 2025 12:01 PM GMT
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical